SCHEMBL5017807

SCHEMBL5017807

Nc1cc(O)nc(-c2nccs2)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 3/20 0.49
HSP90AA1 P07900 1/20 0.45
SMPD3 Q9NY59 1/20 0.38
ALDH1A1 P00352 1/20 0.38
TSHR P16473 1/20 0.38
NOS1 P29475 1/20 0.38
HSD17B10 Q99714 1/20 0.38
ADORA1 P30542 2/20 0.37
CYP1A1 P04798 5/20 0.36
CYP1A2 P05177 5/20 0.36
CYP1B1 Q16678 5/20 0.36
CHEK2 O96017 1/20 0.36
RAB9A P51151 1/20 0.36
SPHK2 Q9NRA0 1/20 0.36
SPHK1 Q9NYA1 1/20 0.36
PDPK1 O15530 1/20 0.35
LOXL2 Q9Y4K0 1/20 0.35
HDAC2 Q92769 2/20 0.35
SYK P43405 2/20 0.34
HDAC3 O15379 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13090462 0.87 ADORA2A (0.47) ADORA2AHSP90AA1SMPD3ALDH1A1CYP1A1
SCHEMBL1489975 0.84 HSP90AA1 (0.54) ADORA2AHSP90AA1ALDH1A1TSHRNOS1
SCHEMBL2549740 0.79 ADORA2A (0.49) ADORA2AHSP90AA1SMPD3ALDH1A1TSHR
SCHEMBL929763 0.74 HSP90AA1 (0.59) ADORA2AHSP90AA1SMPD3ALDH1A1TSHR
SCHEMBL2547481 0.73 HSP90AA1 (0.53) ADORA2AHSP90AA1ALDH1A1TSHRNOS1
SCHEMBL13147657 0.71 IDH1 (0.41) ADORA2AHSP90AA1ADORA1CYP1A1CYP1A2
SCHEMBL5026281 0.71 CYP19A1 (0.48) ADORA2AHSP90AA1ALDH1A1HSD17B10ADORA1
SCHEMBL5017693 0.71 HSP90AA1 (0.47) ADORA2AHSP90AA1ALDH1A1HSD17B10ADORA1
SCHEMBL5024950 0.70 MYC (0.55) ADORA2AHSP90AA1ALDH1A1TSHRHSD17B10
SCHEMBL5016332 0.70 MYC (0.55) ADORA2AHSP90AA1ALDH1A1HSD17B10ADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080058356-A1 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists NEUROCRINE BIOSCIENCES, INC. (US) 2008-03-06 US disclosed
CN-1953975-A 2, 6 bisheteroaryl-4-aminopyrimidines as adenosine receptor antagonists ALMIRALL PRODESFARMA AG (CH) 2007-04-25 CN disclosed
EP-1697351-A1 2,6-BISHETEROARYL-4-AMINOPYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS Almirall Prodesfarma AG (CH) 2006-09-06 EP disclosed
WO-2005058883-A1 2, 6 BISHETEROARYL-4-AMINOPYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS ALMIRALL PRODESFARMA AG (CH) 2005-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058356-A1 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists ADORA2A, ADORA3, ADORA1 ADORA2A 1/4885HSP90AA1 4315/4885SMPD3 2477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.